42nd Annual FDA Boot Camp

On March 13, Washington, D.C. litigation head Jennifer Bragg participated in the panel “Exploring the Subtleties and Safe Zones of Off-Label Communications” during ACI’s 42nd FDA Boot Camp. The panel unpacked the Food and Drug Administration’s current position on the First Amendment and off-label promotion; the 21st Century Cures Act; FDAMA 114; what to expect concerning proposed legislation, rule changes and citizen petitions; and cases and controversies involving state attorneys general actions and private tort claims.